Evidence-Based Complementary and Alternative Medicine / 2015 / Article / Tab 1

Review Article

Danhong Injection (a Traditional Chinese Patent Medicine) for Acute Myocardial Infarction: A Systematic Review and Meta-Analysis

Table 1

Characteristics of included studies.

IDDiagnostic criteriaType of AMISample size (I/C)BaselineDuration of treatmentFollow-upExperiment groupControl groupOutcomes

Gao et al. 2008 [24]2004 ACC/AHASTEMI61 (31/30)Yes2 weeks2 weeksCT + DHI
40 mL.qd.ivd.gtt
CT (+PCI)Recurrent angina, ECG, and aPTT

Gui 2009 [25]Not specificUnclear48 (26/22)Yes2 weeks2 weeksCT + DHI
20 mL.qd.ivd.gtt
CT (+thrombolysis)Mortality, recurrent AMI, shock, HF, arrhythmia, rehospitalization, recurrent angina, and adverse events

Qiao et al. 2010 [26]Not specificUnclear80 (40/40)Yes (narrative only)2–4 weeks2–4 weeksCT + DHI
40 mL.qd.ivd.gtt
CTArrhythmia, HF, shock, reperfusion, and LEVF

Han 2010 [27]Not specificUnclear100 (50/50)Yes (narrative only)4 weeks4 weeksCT + DHI
20 mL.qd.ivd.gtt
CT (+thrombolysis)Mortality, adverse events, and reperfusion rate

Jin et al. 2011 [28]Not specificUnclear60 (30/30)Yes2 weeks2 weeksCT + DHI
30 mL.qd.ivd.gtt
CT (+thrombolysis)Myocardial enzyme, arrhythmia, LEVF, WMSI, ECG, t-PA, PAI-1, CRP, and Fib

Tian 2011 [29]WHOSTEMI72 (36/36)Yes (narrative only)2 weeks2 weeksCT + DHI
30 mL.qd.ivd.gtt
CTRecurrent angina, HF, arrhythmia, ECG, and BP

Hao and Ren 2011 [30]2001 CSCCMAUnclear120 (60/60)Yes (narrative only)Not specificNot specificCT + DHI
30 mL.qd.ivd.gtt
CT (+thrombolysis)Mortality, shock, HF, reperfusion, arrhythmia, and adverse events

Zhao 2012 [31]Not specificUnclear56 (30/26)Yes2 weeks2 weeks/3 monthsCT + DHI
30 mL.qd.ivd.gtt
CT (+thrombolysis)Mortality, myocardial enzyme, HF, arrhythmia, recurrent AMI, LEVF, rehospitalization, and reperfusion

Han et al. 2012 [32]2001 CSCCMAUnclear134 (76/58)Yes (narrative only)2 weeks4 weeksCT + DH
30 mL.qd.ivd.gtt
CT (+thrombolysis)ECG, arrhythmia, myocardial enzyme, reperfusion, HF, shock, recurrent angina, mortality, and adverse events

Zhang 2012 [33]2001 CSCCMAUnclear60 (30/30)Yes1 week1 weekCT + DHI
30 mL.qd.ivd.gtt
CT (+thrombolysis)Arrhythmia, recurrent angina, HF, myocardial enzyme, hs-CRP, NT-pro-BNP, and adverse events

Lu 2012 [34]2009 CSCCMANSTEMI40 (20/20)Yes7–10 days7–10 daysCT + DHI
20 mL.qd.ivd.gtt
CT (+PCI)IL-6, NO, ET, arrhythmia, LEVF, myocardial enzyme, and adverse events

Fan and Zheng 2013 [35]Not specificUnclear90 (47/43)Yes (narrative only)Not specificNot specificCT + DHI
(without specific usage)
CT (+thrombolysis)Mortality, HF, shock, reperfusion, and arrhythmia

Qu et al. 2013 [36]2010 CSCCMAUnclear58 (29/29)Yes2 weeks2 weeksCT + DHI
40 mL.qd.ivd.gtt
CT (+thrombolysis)Arrhythmia, recurrent angina, myocardial enzyme, reperfusion, WMSI, and LEVF

Notes: AHA: American Heart Association; ACC: American College of Cardiology; WHO: World Health Organization; CT: conventional therapy; DHI: Danhong injection; ECG: electrocardiography; CSCCMA: Chinese Society of Cardiology of Chinese Medical Association; recurrent AMI: recurrent acute myocardial infarction; STEMI: ST-segment elevation myocardial infarction; NSTEMI: non-st-segment elevation myocardial infarction; HF: heart failure; LEVF: left ventricular ejection fraction; WMSI: wall motion score index; NO: Nitric Oxide; ET: endothelin; t-PA: tissue-type plasminogen activator; PAI-1: Plasminogen Activator Inhibitor 1; CRP: C-reaction protein; hs-CRP: high-sensitivity CRP; Fib: fibrinogen; NT-pro-BNP: n-terminal probrain natriuretic peptide; IL-6: interleukin-6; PCI: percutaneous coronary intervention.